NMN (Nicotinamide
Mononucleotide)
NMN is a precursor to NAD+ that shows early promise for metabolic, cognitive, and aging-related benefits, but robust human evidence is limited.
Nicotinamide Mononucleotide (NMN) is a nucleotide and direct precursor to NAD+, a key molecule for cellular energy production and metabolism. Supplemental NMN is being explored for its potential to slow age-related NAD+ decline and support metabolic, cognitive, and cardiovascular health. While generally well-tolerated and showing promising animal and early human data, its long-term safety and efficacy remain under study.
Most data come from animal studies and a small number of short-term human trials. Human evidence for clinical benefits is preliminary.
Supports metabolic health and insulin sensitivity
LimitedMay improve insulin sensitivity and blood sugar control in individuals with impaired glucose tolerance or prediabetes.
Enhances physical performance in older adults
LimitedSupplementation increased aerobic capacity and walking distance in some middle-aged and older adults.
Potential cognitive and neuroprotective support
LimitedMay help protect against age-related cognitive decline by boosting neuronal NAD+ levels, though human evidence is preliminary.
Potential cardiovascular support
TheoreticalAnimal research suggests NMN may preserve arterial function and reduce oxidative stress, but human data are lacking.
Son güncelleme: